Kyowa Kirin is a pharmaceutical company contributing to human health and well-being of people around the world.
Kyowa Kirin, engages in the manufacture and sale of medical products and pharmaceuticals in the therapeutic areas of nephrology, oncology, and immunology in Japan. Its pharmaceutical products include GRAN, a protein that enables a quick recovery from neutropenia and reduces the risk of infection; NESP, an agent for correcting anemia; ESPO, a glycoprotein, which acts as an anemia-relieving treatment for dialysis patients; and CONIEL, a calcium antagonist agent for hypertension and angina pectoris. The company's pharmaceutical products also comprise REGPARA an agent for the treatment of secondary hyperparathyroidism; ALLELOCK/Patanol, which are used as medicine for patients with various types of allergies; and DEPAKENE/TOPINA, antiepileptic agents. It also offers a range of products, including amino acids, nucleic acids, vitamins, and sugars, which are used to produce pharmaceuticals, health foods, foods, cosmetics, and other products; plant growth regulators, feed additives, companion animal-related products, and aquaculture medicinal products; and various types of alcohol for use in alcoholic beverages. In addition, the company manufactures and sells industrial alcohols and solvents for automotive, electronics, and housing industries; performance materials that enable the production of raw materials for lubricants, higher alcohols, and polymeric materials used in various consumer goods; and a range of electronic materials for the information technology industry. Further, it provides seasonings, sweeteners, freeze-dried products, and bakery products and ingredients. The company was founded in 1885 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jun 30, 2022
Ardelyx
|
Post-IPO Debt | $20M | Biotechnology | — |